Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3′LTR

Molecular Therapy

Volumn 17, Issue 9, 2009, Pages 1527-1536

  Urbinati, Fabrizia ^a   Arumugam, Paritha ^a   Higashimoto, Tomoyasu ^a   Perumbeti, Anil ^a   Mitts, Kyle ^a   Xia, Ping ^a   Malik, Punam ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; MESSENGER RNA; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DNA PACKAGING; DNA SYNTHESIS; GENE CASSETTE; GENE EXPRESSION; GENE INSERTION; GENETIC TRANSDUCTION; GENOME SIZE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NONHUMAN; REVERSE TRANSCRIPTION; RNA PROCESSING; TARGET CELL; TRANSGENE; VIRUS ASSEMBLY; VIRUS GENOME; VIRUS PARTICLE; VIRUS RECOMBINATION; VIRUS TITRATION;

BETA-GLOBINS; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; CELL LINE; GENE THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; POLYMERASE CHAIN REACTION; TERMINAL REPEAT SEQUENCES; TRANSDUCTION, GENETIC;

LENTIVIRUS;

EID: 69949150240     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.89     Document Type: Article

References (50)

1. Rivella, S, May, C, Chadburn, A, Rivière, I and Sadelain, M (2003). A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human β-globin gene transfer. Blood 101 2932-2939.
2. Persons, DA, Hargrove, PW, Allay, ER, Hanawa, H and Nienhuis, AW (2003). The degree of phenotypic correction of murine β-thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number. Blood 101: 2175-2183.
3. Imren, S, Payen, E, Westerman, KA, Pawliuk, R, Fabry, ME, Eaves, CJ et al. (2002). Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci USA 99: 14380-14385.
4. Modlich, U, Bohne, J, Schmidt, M, von Kalle, C, Knöss, S, Schambach, A et al. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108: 2545-2553.
5. Thrasher, AJ, Gaspar, HB, Baum, C, Modlich, U, Schambach, A, Candotti, F et al. (2006). Gene therapy: X-SCID transgene leukaemogenicity. Nature 443: E5-6; discussion E6.
6. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
7. Zufferey, R, Dull, T, Mandel, RJ, Bukovsky, A, Quiroz, D, Naldini, L et al. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873-9880.
8. Miyoshi, H, Blömer, U, Takahashi, M, Gage, FH and Verma, IM (1998). Development of a self-inactivating lentivirus vector. J Virol 72: 8150-8157.
9. Kraunus, J, Schaumann, DH, Meyer, J, Modlich, U, Fehse, B, Brandenburg, G et al. (2004). Self-inactivating retroviral vectors with improved RNA processing. Gene Ther 11: 1568-1578.
10. Felsenfeld, G, Burgess-Beusse, B, Farrell, C, Gaszner, M, Ghirlando, R, Huang, S et al. (2004). Chromatin boundaries and chromatin domains. Cold Spring Harb Symp Quant Biol 69: 245-250.
11. Rivella, S, Callegari, JA, May, C, Tan, CW and Sadelain, M (2000). The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol 74: 4679-4687.
12. Emery, DW, Yannaki, E, Tubb, J, Nishino, T, Li, Q and Stamatoyannopoulos, G (2002). Development of virus vectors for gene therapy of β chain hemoglobinopathies: Flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 100: 2012-2019.
13. Ramezani, A, Hawley, TS and Hawley, RG (2003). Performance- and safety-enhanced lentiviral vectors containing the human interferon-β scaffold attachment region and the chicken β-globin insulator. Blood 101: 4717-4724.
14. Arumugam, PI, Scholes, J, Perelman, N, Xia, P, Yee, JK and Malik, P (2007). Improved human β-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther 15: 1863-1871.
15. Puthenveetil, G, Scholes, J, Carbonell, D, Qureshi, N, Xia, P, Zeng, L et al. (2004). Successful correction of the human β-thalassemia major phenotype using a lentiviral vector. Blood 104: 3445-3453.
16. Evans-Galea, MV, Wielgosz, MM, Hanawa, H, Nienhuis, AW (2006). Suppression of clonal dominance in cultured human lymphoid cells by addition of 5' cHS4 insulator to a lentiviral vector. Mol Ther 13: S405.
17. Ryu, BY, Persons, DA, Evans-Galea, MV, Gray, JT and Nienhuis, AW (2007). A chromatin insulator blocks interactions between globin regulatory elements and cellular promoters in erythroid cells. Blood Cells Mol Dis 39: 221-228.
18. Junker, U, Böhnlein, E and Veres, G (1995). Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy. Gene Ther 2: 639-646.
19. Shin, NH, Hartigan-O'Connor, D, Pfeiffer, JK and Telesnitsky, A (2000). Replication of lengthened Moloney murine leukemia virus genomes is impaired at multiple stages. J Virol 74: 2694-2702.
20. Gélinas, C and Temin, HM (1988). The v-rel oncogene encodes a cell-specific transcriptional activator of certain promoters. Oncogene 3: 349-355.
21. Coffin, JM (1990). Retroviridae and their replication. In: Fields, BN (ed). Feilds Virology 2nd edn., Raven Press: New York, pp. 1437-1500.
22. Kumar, M, Keller, B, Makalou, N and Sutton, RE (2001). Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 12: 1893-1905.
23. Chung, JH, Bell, AC and Felsenfeld, G (1997). Characterization of the chicken β-globin insulator. Proc Natl Acad Sci USA 94: 575-580.
24. Recillas-Targa, F, Bell, AC and Felsenfeld, G (1999). Positional enhancer-blocking activity of the chicken β-globin insulator in transiently transfected cells. Proc Natl Acad Sci USA 96: 14354-14359.
25. Julias, JG, Ferris, AL, Boyer, PL and Hughes, SH (2001). Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase. J Virol 75: 6537-6546.
26. Brulé, F, Bec, G, Keith, G, Le Grice, SF, Roques, BP, Ehresmann, B et al. (2000). In vitro evidence for the interaction of tRNA(3)(Lys) with U3 during the first strand transfer of HIV-1 reverse transcription. Nucleic Acids Res 28: 634-640.
27. Ohi, Y and Clever, JL (2000). Sequences in the 5' and 3' R elements of human immunodeficiency virus type 1 critical for efficient reverse transcription. J Virol 74: 8324-8334.
28. Topping, R, Demoitie, MA, Shin, NH and Telesnitsky, A (1998). Cis-acting elements required for strong stop acceptor template selection during Moloney murine leukemia virus reverse transcription. J Mol Biol 281: 1-15.
29. Pathak, VK and Temin, HM (1990). Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: Deletions and deletions with insertions. Proc Natl Acad Sci USA 87: 6024-6028.
30. Zhuang, J, Jetzt, AE, Sun, G, Yu, H, Klarmann, G, Ron, Y et al. (2002). Human immunodeficiency virus type 1 recombination: Rate, fidelity, and putative hot spots. J Virol 76: 11273-11282.
31. Herman, SA and Coffin, JM (1987). Efficient packaging of readthrough RNA in ALV: Implications for oncogene transduction. Science 236: 845-848.
32. Schambach, A, Galla, M, Maetzig, T, Loew, R and Baum, C (2007). Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther 15: 1167-1173.
33. Higashimoto, T, Urbinati, F, Perumbeti, A, Jiang, G, Zarzuela, A, Chang, LJ et al. (2007). The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors. Gene Ther 14: 1298-1304.
34. Zaiss, AK, Son, S and Chang, LJ (2002). RNA 3' readthrough of oncoretrovirus and lentivirus: Implications for vector safety and efficacy. J Virol 76: 7209-7219.
35. Heilman-Miller, SL, Wu, T and Levin, JG (2004). Alteration of nucleic acid structure and stability modulates the efficiency of minus-strand transfer mediated by the HIV-1 nucleocapsid protein. J Biol Chem 279: 44154-44165.
36. Berkhout, B, Vastenhouw, NL, Klasens, BI and Huthoff, H (2001). Structural features in the HIV-1 repeat region facilitate strand transfer during reverse transcription. RNA 7: 1097-1114.
37. Zuker, M (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415.
38. Butler, SL, Hansen, MS and Bushman, FD (2001). A quantitative assay for HIV DNA integration in vivo. Nat Med 7: 631-634.
39. Brown, PO, Bowerman, B, Varmus, HE and Bishop, JM (1987). Correct integration of retroviral DNA in vitro. Cell 49: 347-356.
40. Bukrinsky, MI, Sharova, N, Dempsey, MP, Stanwick, TL, Bukrinskaya, AG, Haggerty, S et al. (1992). Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci USA 89: 6580-6584.
41. Zennou, V, Petit, C, Guetard, D, Nerhbass, U, Montagnier, L and Charneau, P (2000). HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101: 173-185.
42. Hansen, MS, Smith, GJ, Kafri, T, Molteni, V, Siegel, JS and Bushman, FD (1999). Integration complexes derived from HIV vectors for rapid assays in vitro. Nat Biotechnol 17: 578-582.
43. Miller, MD, Farnet, CM and Bushman, FD (1997). Human immunodeficiency virus type 1 preintegration complexes: Studies of organization and composition. J Virol 71: 5382-5390.
44. Lotti, F, Menguzzato, E, Rossi, C, Naldini, L, Ailles, L, Mavilio, F et al. (2002). Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement. J Virol 76: 3996-4007.
45. Bordignon, C, Notarangelo, LD, Nobili, N, Ferrari, G, Casorati, G, Panina, P et al. (1995). Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270: 470-475.
46. Hantzopoulos, PA, Sullenger, BA, Ungers, G and Gilboa, E (1989). Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc Natl Acad Sci USA 86: 3519-3523.
47. Wiznerowicz, M, Fong, AZ, Mackiewicz, A and Hawley, RG (1997). Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: Application to melanoma vaccine development. Gene Ther 4: 1061-1068.
48. Ilves, H, Barske, C, Junker, U, Böhnlein, E and Veres, G (1996). Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: A comparative study. Gene 171: 203-208.
49. Moreau-Gaudry, F, Xia, P, Jiang, G, Perelman, NP, Bauer, G, Ellis, J et al. (2001). High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood 98: 2664-2672.
50. Yáñez-Muñoz, RJ, Balaggan, KS, MacNeil, A, Howe, SJ, Schmidt, M, Smith, AJ et al. (2006). Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 12: 348-353.